Vertex, CRISPR Therapeutics Get FDA Approval for First CRISPR Gene-Editing Therapy in USInvestopedia • 12/08/23
Vertex and CRISPR Therapeutics Announce US FDA Approval of CASGEVY™ (exagamglogene autotemcel) for the Treatment of Sickle Cell DiseaseBusiness Wire • 12/08/23
Crispr Therapeutics, Vertex get FDA approval for breakthrough gene-editing treatmentMarket Watch • 12/08/23
U.S. poised to approve first gene-editing treatment in breakthrough for sickle cell patientsCNBC • 12/07/23
This Newly Discovered Risk Could Be a Big Headache for Vertex Pharmaceuticals and CRISPR TherapeuticsThe Motley Fool • 12/07/23
RoslinCT to manufacture exagamglogene autotemcel (exa-cel) for Vertex Pharmaceuticals Inc following an extensive development collaborationGlobeNewsWire • 11/28/23